...The compound could find uses in other indications. An ongoing investigator-led trial run from the University Medical Center Hamburg-Eppendorf...

...3895 Protein S (PROS1) MM Mouse; cell-based Overexpression of PROS1 promotes destructive myeloma bone disease. University Medical Center Hamburg-Eppendorf...

...difficulty escaping the liver -- into an advantage. The discovery underlying the technology originated at University Medical Center Hamburg-Eppendorf...

...difficulty escaping the liver -- into an advantage. The discovery underlying the technology originated at University Medical Center Hamburg-Eppendorf...

...published online Nov. 23, 2016 doi:10.1126/scitranslmed.aaf8463 CONTACT: Friedrich Koch-Nolte, University Medical Center Hamburg-Eppendorf, Hamburg, Germany email: nolte@uke.de Hongjiang Li University Medical Center Hamburg-Eppendorf Interleukin-1...

...pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease.” Science (2016) - Michael Leviten Michael Leviten University Medical Center Hamburg-Eppendorf Interleukin-22...

...Labberton, L. et al. Nat. Comm.; published online Sept. 6, 2016 doi:10.1038/ncomms12616 CONTACT: Thomas Renné, University Medical Center Hamburg-Eppendorf...

...of the peptides," said CEO Timm Jessen. The discovery underlying the company's technology originated at University Medical Center Hamburg-Eppendorf...
...Applied Nanotechnology GmbH, Hamburg, Germany Evotec AG (Xetra:EVT), Hamburg, Germany Topas Therapeutics GmbH, Hamburg, Germany University Medical Center Hamburg-Eppendorf...
...Clinical status: Preclinical Founded: 2016 by Timm Jessen, John Pohlner and Evotec AG University collaborators: University Medical Center Hamburg-Eppendorf...

...I testing of its unnamed lead product to treat multiple sclerosis. The product originated at University Medical Center Hamburg-Eppendorf...

...universities when it acquired Bionamics GmbH in 2014. Topas' platform was exclusively licensed from the University Medical Center Hamburg-Eppendorf...